Trial Profile
LEEP study A Randomised controlled Phase II trial of the pharmacodynamic effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms LEEP
- 19 Mar 2019 Status changed from not yet recruiting to recruiting.
- 12 Mar 2018 New trial record